Arana Therapeutics Limited

 
 
     

View in Other Languages

News

Australian Market Report of March 5: Good Leads from China and the US

🕔3/5/2009 1:00:21 PM 15376

Yesterday the Australia market stayed on the red for the third consecutive day. Both the Aussie dollar and the S&P 200 Index fell lower on the news of the latest GDP figures. The benchmark S&P/ASX200 index ended down 1.6%, or 52.8 points, at 3166.4, while the All Ordinaries index loses 1.4%, or 45.5 points, at 3125.9.

Read Full Article

Australian Market Report of March 2: Refocus after Reporting Season

🕔3/2/2009 1:00:18 PM 18341

The Australian stocks closed Friday with little change after falls from early highs. The benchmark S&P/ASX200 index declined one point, or 0.03 per cent, to 3344.5, while the broader All Ordinaries fell half a point, or 0.02 per cent, to 3296.9. With the reporting seasons over, the market focus will return to the economic data and RBA's rate cut decision this week.

Read Full Article

Arana Therapeutics Excellence In Biotechnology Investment - Mr John Chiplin, CEO, Arana Therapeutics

🕔5/5/2008 10:41:00 AM 7453

Arana Therapeutics Excellence in Biotechnology Investment - Mr John Chiplin, CEO, Arana Therapeutics; Arana Therapeutics (ASX: AAH) present the following audio webcast regarding "Excellence in Biotechnology Investment - Mr John Chiplin, CEO, Arana Therapeutics". You may also download this audio webcast to your computer or portable audio player.

Read Full Article

Peptech ASX: PTD - Shareholders Approve Peptech-Evogenix Merger - Dr John Chiplin, CEO

🕔8/9/2007 2:17:00 PM 8066

Peptech (ASX: PTD) - Shareholders Approve Peptech-Evogenix Merger - Dr John Chiplin, CEO; Peptech (ASX: PTD) present the following audio webcast regarding "Shareholders Approve Peptech-Evogenix Merger". You may also download this audio webcast to your computer or portable audio player.

Read Full Article

Peptech ASX: PTD - Peptech Presentation To Eg Capital Forum - Dr John Chiplin, CEO

🕔7/12/2007 11:45:00 AM 8946

Peptech (ASX: PTD) - Peptech presentation to eG Capital Forum - Dr John Chiplin, CEO; Peptech (ASX: PTD) present the following audio webcast regarding "Peptech presentation to eG Capital Forum".

Read Full Article

Peptech ASX: PTD - Merger Roadshow Presentation - Dr John Chiplin, MD; Dr Phil Jennings, Exec. Director and Dr Cliff Holloway, VP of Bus. Development

🕔6/6/2007 10:49:00 AM 7885

Peptech (ASX: PTD) - Merger Roadshow Presentation - Dr John Chiplin, MD; Dr Phil Jennings, Exec.

Read Full Article

Peptech ASX: PTD - Enters Phase I Clinical Trials - Dr Phil Jennings, Executive Director

🕔5/22/2007 1:22:00 PM 6535

Peptech (ASX: PTD) - Enters Phase I Clinical Trials - Dr Phil Jennings, Executive Director; Boardroomradio is pleased to announce that Peptech (ASX: PTD) has published an audio file.

Read Full Article

Peptech ASX: PTD - Record Profit for Half Year - Dr John Chiplin, MD

🕔5/17/2007 3:55:00 PM 6348

Peptech (ASX: PTD) - Record Profit for Half Year - Dr John Chiplin, MD; Boardroomradio is pleased to announce that Peptech (ASX: PTD) has published an audio file.

Read Full Article

Peptech ASX: PTD - Peptech & EvoGenix Merge to Form Antibody Powerhouse - Dr John Chiplin and Dr Merilyn Sleigh

🕔5/7/2007 11:52:00 AM 6918

Peptech (ASX: PTD) - Peptech & EvoGenix Merge to Form Antibody Powerhouse - Dr John Chiplin and Dr Merilyn Sleigh; Boardroomradio is pleased to announce that Peptech (ASX: PTD) has published an audio file.

Read Full Article

Peptech ASX: PTD - Suprelorin Recommendation Clears Path for Sales in Europe - Dr Paul Schober, General Manager, Peptech Animal Health

🕔3/21/2007 2:25:00 PM 4404

Peptech (ASX: PTD) - Suprelorin Recommendation Clears Path for Sales in Europe - Dr Paul Schober, General Manager, Peptech Animal Health; Boardroomradio is pleased to announce that Peptech (ASX: PTD) has published an audio file.

Read Full Article
###

53,923 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 8) (Last 30 Days: 94) (Since Published: 13183) 

Company Data

    Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Listed
  • 1986/01/23